AT13148

AT13148 is an orally active, ATP-competitive small molecule inhibitor that targets multiple AGC kinases, most notably Rho-associated protein kinase (ROCK) and protein kinase B (AKT). It was developed as a dual ROCK-AKT inhibitor with the aim of blocking cancer cell proliferation and metastasis by inhibiting key signaling pathways involved in tumor growth and survival. Preclinical studies demonstrated anti-metastatic and anti-proliferative activity across several cancer models. In clinical trials, AT13148 was evaluated for advanced solid tumors but did not demonstrate significant tumor shrinkage; its development was discontinued due to a narrow therapeutic index and unfavorable pharmacokinetic profile[1][5][6].